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Abstract: Tuberculosis infection is of global public health significance, with millions of incident 
cases each year. Many cases, particularly in low-prevalence settings, result from the reactiva-
tion of latent tuberculosis infection (LTBI); potentially acquired years prior to active disease. 
Up to one-third of the world’s population has been infected with LTBI, and so may be at risk 
for future active TB disease. A variety of antituberculosis medications and treatment regimens 
have now been evaluated in the management of LTBI, with the aim of eradicating tuberculosis 
bacilli and reducing the likelihood of subsequent reactivation disease. This article reviews LTBI 
therapies and their use in clinical contexts, and considers future directions for individual and 
population-based strategies in LTBI management.
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Introduction
It is estimated that active tuberculosis (TB) infection results in 9–10 million   incident 
cases and around 1.8 million deaths annually.1 Estimates of the prevalence of latent 
tuberculosis infection (LTBI) are considerably less precise, but it is commonly 
  suggested that up to one-third of the world’s population may be affected and at risk 
of subsequent reactivation. LTBI is therefore a condition of considerable importance. 
This is particularly so in settings with a low prevalence of active TB, where the   majority 
of infections relate to reactivation of latent disease.
LTBI is by definition an asymptomatic condition. There is no gold standard test 
for LTBI, and establishing a diagnosis may involve elements of medical history, chest 
X-ray, tuberculin skin test (TST), or interferon-gamma release assay (IGRA). Uncer-
tainty related to the diagnosis makes rational public health use of LTBI treatment 
difficult, and better tools for estimating population prevalence are required. Although 
there continues to be uncertainty regarding the precise likelihood of reactivation in 
individuals, patients with LTBI may experience reactivation decades after exposure, 
with an often quoted summary estimate of 10% lifetime risk of progressing to active 
infection.2 A variety of antituberculosis medications and treatment regimens have been 
evaluated in the management of LTBI, with the aim of eradicating tuberculosis bacilli 
and reducing the likelihood of subsequent reactivation disease.
This article will review LTBI therapies and their use in clinical contexts, and will 
consider future directions for individual and population-based strategies in LTBI 
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Dovepress 
Dovepress
64
Denholm and McBryde
General principles of LTBI therapy
The antimicrobial agents used for the treatment of active 
tuberculosis are also those used and investigated for LTBI. 
However, not all medications effective against active 
  tuberculosis are necessarily appropriate for the treatment of 
LTBI. Medications must be active against the latent phase of 
M. tuberculosis and be sufficiently well-tolerated for   treatment 
of an asymptomatic condition. Preferably, they should also 
require little regular monitoring,   sterilize   mycobacteria 
quickly and have a high threshold to the   development of 
microbial resistance.
Treatment of LTBI at present requires extended courses 
of effective antituberculosis therapy. Although strategies are 
being investigated to shorten the duration of these   treatment 
regimens, it is expected that the long latent periods and slow 
replicative cycle of M. tuberculosis will mean that treatment 
with existing agents will continue to be relatively lengthy 
for the foreseeable future. Accordingly, all regimens for the 
treatment of LTBI currently in use require months of daily 
anti-tuberculosis medications. Lengthy courses of therapy 
in asymptomatic patients are typically associated with 
high rates of poor adherence and loss to follow-up, with 
resultant decrease in efficacy of LTBI treatment programs.3 
Strategies to improve adherence with therapy have included 
educational programs, support from pharmacists and other 
allied health care providers, medication alarms and reminder 
systems; however the establishment of effective short-course 
regimens are ultimately likely to provide the most benefit in 
this setting.4–6
In an attempt to improve compliance, intermittent 
  dosing strategies for various LTBI regimens have been 
investigated, such as twice-weekly isoniazid instead of daily 
  administration. These approaches will be reviewed in more 
detail below; however as a general principle, non-compliance 
is more likely to impact outcome if the regimen is   intermittent 
rather than daily. Accordingly, it is recommended that all 
non-daily dosing schedules be administered by directly 
observed therapy (DOT) to ensure compliance.
Typically, antimicrobial agents for LTBI have been pre-
scribed as monotherapy, most commonly with isoniazid or 
rifampicin (see below). In the setting of active tuberculosis, 
the use of single-medication therapy clearly leads to the 
development of antimicrobial resistance. For instance, when 
  isoniazid alone was used for disease treatment, 71% of patients 
developed resistance after three months.7 Rather than being 
caused by the induction of resistance in individual organisms, 
this is believed to be due to the selection of small numbers 
of naturally resistant M. tuberculosis   organisms present at 
the time of treatment. However, the low number of bacilli 
  present in latent tuberculosis   infections means that the pres-
ence of any such naturally resistant organisms is   uncommon, 
and monotherapy is generally effective. In   situations where 
there is a high probability of drug-resistant organisms pres-
ent, such a principle does not remain reliable, and alternative 
strategies may be required (see below).
As LTBI itself is an asymptomatic condition,   treatment 
is given based on the risk of future reactivation. The 
  decision to treat, therefore, involves a weighing of the risk 
of therapy against benefit from reduction in reactivation 
for the individual patient. Such decisions will necessarily 
be influenced by factors that either increase risk of reac-
tivation (such as recent contact with active tuberculosis 
or the impending introduction of immunosuppressive 
medication) or risk of serious adverse effects of therapy 
(such as advanced age or pre-existing hepatotoxicity). In 
most settings, these factors are sufficiently varied that 
treatment decisions must be individually considered and 
made, rather than being applicable to broader populations 
outside of limited settings.
Overall, while the effectiveness of treatment for LTBI 
is clear from large studies such as those described here, 
it is important to recognize that there remains no test or 
method for determining whether treatment have been 
  effective in the individual patient. Patients therefore should 
be   counseled that treatment success cannot be guaranteed, 
and symptoms consistent with active tuberculosis should 
be investigated   appropriately even following completion of 
LTBI treatment.
LTBI in people with HIV
Co-infection with HIV and tuberculosis is recognized as a 
significant issue worldwide. Although much of this awareness 
relates to the problems associated with active infection, the 
diagnosis and treatment of LTBI in people with HIV presents 
additional difficulties. Although HIV-positive people may be 
no more likely to be exposed to tuberculosis, once exposed 
they have considerably increased risk of progression to active 
disease, whether primary or secondary.8 Active   tuberculosis 
is less likely to present in classic pulmonary forms in 
people co-infected with HIV , and it may be more difficult to 
exclude active infection than in those without HIV .9–11 This 
is problematic for the appropriate management of LTBI, 
as initiating therapy in the setting of unrecognized active 
  infection may lead to treatment failure and the development 
of anti-tuberculosis drug resistance. For instance, one study 
of HIV-infected subjects in Cote d’Ivoire found that 1.9% of Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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enrolled subjects had active tuberculosis at baseline, despite 
clinical screening intended to exclude such patients.12
Interactions between antiretroviral medications and 
treatment for LTBI may also be an important issue in both 
safety and effectiveness, and is dealt with in the relevant 
sections below.
Regimens for treatment of LTBI
Isoniazid
By far the most established and widely used   medication for 
the treatment of LTBI is isoniazid. First identified in the early 
1950’s, isoniazid has multiple effects on   mycobacterial metab-
olism, including inhibition of mycolic acid synthesis.13,14 Sev-
eral dosing strategies are commonly employed, with   evidence 
for both daily self-administered therapy and   supervised admin-
istration (DOT) twice weekly in some   settings. A summary 
of current dosing   recommendations from the US Centers for 
Disease Control and Prevention can be seen in Table 1.
Initial human trials of isoniazid preventative therapy estab-
lished that prolonged therapy with isoniazid was effective in 
reducing subsequent active tuberculosis   infections. In one 
of the earliest studies conducted, 800 Kenyan   tuberculosis 
contacts were randomized to either receive 12 months of iso-
niazid or placebo.15 A 90% reduction in active TB   diagnosis 
Table 1 Dosing regimens for tuberculosis 
Drug/dose Frequency/ 
duration
Rating (evidence)
HIV 
negative
HIV 
positive
Preferred Regimen 
Isoniazid 
Adult: 5 mg/kg 
Children: 10–20 mg/kg 
Maximum dose 300 mg
Daily ×  
9 months
A (II) A (II)
Alternate Regimens
Isoniazid 
Adult: 15 mg/kg 
Children: 20–40 mg/kg 
Maximum dose 900 mg
Twice weekly ×  
9 months
B (II) B (II)
Isoniazid 
Adults: 5 mg/kg 
Maximum dose 300 mg
Daily ×  
6 months
B (I) C (I)
Isoniazid 
Adults: 15 mg/kg 
Maximum dose  900 mg
Twice weekly ×  
6 months
B (II) C (I)
Rifampin 
Adults: 10 mg/kg 
Children: 10–20 mg/kg 
Maximum dose 600 mg
Daily ×  
4 months
B (II) B (II)
Notes: Reproduced from: Centers for Disease Control and Prevention. Guide 
for Primary Health Care Providers: Targeted tuberculin testing and treatment of 
latenttuberculosis infection. CDC, 2005. Available at www.cdc.gov/tb/publications/
LTBI/intro.htm
was observed in the isoniazid intervention arm, with 17 versus 
2 patients developing active infections after 1 year. Studies 
investigating the use of longer courses found that no significant 
additive benefit accrued beyond 12 months of therapy.16 Sub-
sequent studies investigated the potential of shorter courses of 
isoniazid therapy, such as the large International Union Against 
Tuberculosis (IUAT) trial.17 This international multicenter 
study randomized 28,000 subjects with fibrotic pulmonary 
lesions to receive 3, 6, or 12 months of isoniazid treatment 
(previously known as isoniazid preventive therapy, or IPT) 
or placebo, with follow-up   continued for 5 years. While 12 
months of isoniazid therapy prevented the largest number cases 
of active tuberculosis (75% reduction from placebo; compared 
to 21% and 65% with 3 and 6 months, respectively), it was 
also associated with a higher rate of serious hepatotoxicty. 
The study concluded that 6 months was the optimal duration, 
as it prevented the greatest number of tuberculosis infections 
per episode of hepatitis caused. Subsequently, a re-analysis of 
these results suggested that amongst patients compliant with 
treatment, this reduction was 69% for 6 months of isoniazid 
and 93% for 12 months.18 This analysis also reviewed addi-
tional studies and recommended that the optimal duration 
of treatment was likely to be ‘9 or 10 months’, although no 
specific trial data was available for this duration of therapy. 
Nonetheless this recommendation has become widely adopted, 
particularly in the United States where it forms the basis for 
national guidelines recommending this duration.
Isoniazid therapy in people with HIv
With widespread co-infection of HIV and TB, particularly 
in Sub-Saharan Africa, the effectiveness of isoniazid pre-
ventative therapy in various clinical settings with high HIV 
prevalence has also been explored. One placebo-controlled 
trial of 12 months of isoniazid in HIV-infected children has 
been conducted, in which HIV-infected infants in a high preva-
lence TB area were enrolled.19 Children were predominantly 
not receiving highly active anti-retroviral therapy. This study 
was stopped early after an interim report found a significant 
reduction in tuberculosis diagnosis and mortality in children 
receiving isoniazid (8% vs 16% after a mean follow-up of 
5.7 months). A follow up report on this study population 
suggested a very high compliance with prescribed therapy 
(.90%).20
The long-term benefits of routine LTBI treatment in high 
prevalence settings are unknown, and further studies will be 
required to determine optimal strategies, including appropri-
ate settings, duration of use and impact on   drug-resistance 
in subsequent active tuberculosis infections. In HIV-infected Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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adults with LTBI, meta-analysis of published studies has 
confirmed that isoniazid therapy is effective in preventing 
progression to active infection.21 This analysis of seven 
studies, including 4529 subjects, suggested a relative risk 
(RR) of 0.4 (95% confidence interval [CI]: 0.24–0.65) in 
those with a positive TST, while a nonsignificant reduction 
(0.84, 95% CI: 0.54–1.30) was found in those with negative 
baseline testing. However, other studies have shown that 
unselected HIV-positive populations may also benefit from 
LTBI therapy in areas with sufficiently high TB prevalence.22 
Current guidelines recommend that the HIV-positive people 
follow the same treatment protocols for therapy as HIV-
negative people diagnosed with LTBI, with a 9-month course 
as optimal duration.3
Isoniazid treatment in children and adolescents
Isoniazid is regarded as safe in children, and is widely used 
for the treatment of LTBI from infancy. There is an increased 
rate of progression to active TB in children aged less than 
5 years old, and LTBI therapy in this group is highly effec-
tive, perhaps more so than in adults. In households with 
active tuberculosis infection, some studies have estimated 
that up to 30%–40% of children under 15 years may have 
LTBI.23,24 Several large early trials have demonstrated that 
the risk of progression to active disease may be reduced by 
up to 90% with 12-month courses of therapy.25 Accordingly, 
WHO guidelines recommend that all TB-exposed children 
in whom active infection has been excluded receive a course 
of treatment for LTBI, however this is not routinely provided 
in many developing world settings.26,27
Isoniazid treatment in pregnancy and lactation
Isoniazid does not have teratogenic effects in humans, and 
has been widely used in regimens for the treatment of active 
infections in pregnancy.28,29 Serious hepatotoxity has been 
reported during isoniazid use in pregnancy, and one retrospec-
tive analysis of cases suggested a 2.5-fold (but not statistically 
significant) increase in hepatotoxicty in this setting.30,31 Treat-
ment for LTBI in pregnancy is sometimes deferred until after 
delivery for this reason, as pregnancy per se does not influence 
the risk of TB reactivation.32 However, an evaluation of various 
strategies has concluded that treating LTBI during pregnancy 
with isoniazid would be cost effective and improve overall 
outcomes, with increased hepatotoxicty more than offset 
by decreased tuberculosis infections.33 Guidelines generally 
support treatment of LTBI in pregnancy with isoniazid as the 
preferred option where there is high risk of reactivation, with 
close monitoring of liver function tests recommended.3
Small amounts of active drug are present in breast milk 
when isoniazid is used in lactating women, in insufficient 
amounts for the treatment of LTBI in infants.3 No adverse 
effects on infants have been reported, however it is recom-
mended that pyridoxine be given to breastfeeding infants 
when isoniazid is used in this setting.34
Adverse effects and tolerability
A number of large studies and reviews of isoniazid 
  monotherapy have concluded that the incidence of serious 
hepatitis (ALT . 5 ULN) in young, previously well 
patients is between 0.1%–0.56%, a figure adopted by the 
American Thoracic Society for formulation of guidelines and 
  recommendations.35–37 However, when routine liver function 
testing is performed throughout isoniazid therapy, discontinua-
tion of   medication occurs in around 4%–10% of patients due to 
abnormal results.38–40 In a recent randomized trial, for instance, 
discontinuation due to serious hepatotoxicity was reported 
in 3.8% of patients.40 Patients in this study included those at 
higher risk of side effects, including abnormal baseline LFT 
and those aged .35. The discordance between these liver func-
tion test results and clinical syndromes seen in various studies 
has led to recommendations against routine liver function 
testing during LTBI treatment in low risk patients, particularly 
those aged ,35 with normal baseline liver function.41
Peripheral neuropathy has been recognised in associa-
tion with isoniazid preventive therapy since its inception.42 
Isoniazid leads to neuropathy by competitively inhibiting 
the metabolic activity of pyridoxine, an activity that can be 
overcome in at-risk patients through the co-administration 
of pyridoxine supplementation. A genetic basis for this tox-
icity has been identified in variable acetylation of isoniazid 
between individuals, although malnutrition may also play 
a role in increasing neuropathy risk.43 Co-prescription of 
other neurotoxic agents such as stavudine (D4T) or didanos-
ine should be avoided due to increased rates of peripheral 
neuropathy.44 Unlike the treatment of active tuberculosis, 
treatment regimens for LTBI are not usually supplemented 
by pyridoxine, but it may be considered in high-risk groups, 
including those with pre-existing neuropathy or additional 
risk factors for its development (eg, HIV , diabetes, malnutri-
tion or use of other neurotoxic medications).3
Isoniazid resistance
High prevalence tuberculosis regions worldwide have reported 
increasing rates of isoniazid resistance, with the resulting 
  potential for decreasing effectiveness of   isoniazid-based 
  regimens for LTBI.45 South African serial surveys of Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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  antimicrobial sensitivity found an increase in isoniazid 
  resistance from 6.9% to 12.4% in pediatric TB isolates between 
1994–2005, a significant development in a treatment naïve 
cohort.46 In regions such as Uzbekistan and Azerbaijan, with 
a high proportion of treatment failure and MDR-TB transmis-
sion, reported isoniazid-resistance is as high as 40%–49%.47 
Clearly in   settings such as these, the effectiveness of isoniazid 
treatment will be considerably reduced, and alternative strate-
gies for LTBI management are required.
Rifampicin (rifampin)
Rifampicin acts by inhibiting bacterial DNA polymerase, and 
is currently recommended as second-line therapy for LTBI, 
or for use where the index case is known to be infected with 
isoniazid-resistant tuberculosis.3
Rifampicin has been regarded as an attractive option for 
LTBI treatment due to the possibility of shortening duration 
of therapy, as was seen when the medication was introduced 
into treatment of active tuberculosis. The only randomized 
trial of rifampicin monotherapy for LTBI compared 3 months 
of rifampicin with 6 months of isoniazid therapy in patients 
with silicosis, and concluded that they were equivalent 
in effectiveness.48 A further retrospective study including 
49 people exposed to isoniazid-resistant tuberculosis found 
that none progressed to active disease a mean 26 months 
after LTBI therapy with rifampicin monotherapy; however 
duration of therapy was nonstandardized and often prolonged, 
with a mean duration of more than 6 months.49 In light of 
the probable increased effectiveness of 9 month courses of 
isoniazid over 6 month courses, subsequent adult studies 
have favored treatment regimens longer than 3 months, usu-
ally 4-month courses of rifampicin.50 No study, however, has 
directly compared the effectiveness of 4 months of rifampicin 
against 9 months of isoniazid for the prevention of active 
tuberculosis; a key requirement if this regimen is to be used 
more widely in the future.
Rifampicin therapy in people with HIv
Rifampicin monotherapy for LTBI has not been studied in 
HIV-positive cohorts, with some authorities citing concerns 
about unrecognized active disease and the potential for 
development of rifampicin resistance.51 Rifampicin also 
interacts with a number of common antiretroviral medications 
such as efavirenz, and in particular rifampicin-containing 
regimens should be avoided in patients being treated with 
protease inhibitors (PI), as enzyme induction may lead 
to   sub-therapeutic levels of PI and increased rifampicin 
toxicity.52 Pharmacokinetic studies have suggested that PI 
boosted with ritonavir may still achieve acceptable serum 
levels however there has been no evaluation of LTBI 
therapy in this context, and rifampicin monotherapy is not 
recommended.53
Rifampicin in children and adolescents
Rifampicin is recommended as an alternative to 9 months 
of isoniazid for children. Typically, 4–6 month durations are 
recommended, with no studies directly comparing the two 
regimens. In one series, 157 adolescent patients exposed to 
isoniazid-resistant index cases of tuberculosis were treated 
with a 6-month course of rifampicin, with no progression to 
active disease observed over a 2-year follow-up period.54
Rifampicin in pregnancy and lactation
There are no controlled studies of rifampicin in pregnancy, 
and retrospective reviews are divided regarding any increased 
risk of congenital malformations.32 Use of rifampicin 
for latent tuberculosis is not recommended in pregnancy, 
although it has been used widely in the treatment of active 
tuberculosis in this context.3 Rifampicin is also present in 
breast milk, at low concentrations that are considered safe 
for infants, but nontherapeutic.55
Adverse effects and tolerability
The adverse effects of rifampicin have been compared with 
isoniazid in a recent international randomized trial.40 Patients 
diagnosed with LTBI (n = 847) were randomized to receive 
either 4-month courses of rifampicin or 9 months of isoniazid, 
with early cessation of enrolment due to decreased serious 
adverse events in the rifampicin-receiving arm. Patients 
prescribed isoniazid were more likely to have serious adverse 
events overall (4.0% vs 1.7%), with the bulk of adverse 
events relating to hepatotoxicity. Hepatotoxicity occurred in 
0.7% of patients receiving rifampicin and in 3.8% of patients 
receiving isoniazid. While the number of patients found to 
have developed isoniazid hepatotoxicity in this study is high 
compared to previous investigations, this likely reflects a 
greater-risk patient group and represents a fair assessment 
of the relative toxicity of the two regimens.
Rifampicin and pyrazinamide
Initial studies of 2-month rifampicin and pyrazinamide 
(2RZ) regimens evaluated its effectiveness predominantly 
in settings with a high prevalence of both HIV/AIDS and 
tuberculosis.56 The first of these studies suggested that 2RZ 
moderately reduced the incidence of subsequent TB infection 
(RR 0.58 over 1 year; 95% CI: 0.35–0.95) when compared Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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with placebo; reduction is somewhat less effective than a 
6 month course of isoniazid. This effect waned quickly after 
treatment cessation, likely reflecting TB re-infection in a 
high prevalence setting. Subsequent studies performed in a 
variety of settings confirmed the effectiveness of this regimen, 
resulting to its adoption as an alternative recommendation 
for LTBI therapy.57,58
Between 2000–2002, a number of reports of increased 
frequency of side effects emerged, particularly hepatotox-
icity requiring discontinuation of therapy.59–61 On the basis 
of these reports, a joint recommendation against the use of 
this regimen was issued in 2003 by the Centers for Disease 
Control and Prevention and the American Thoracic Soci-
ety.62 A systematic review of LTBI treatment with 2 month 
rifampicin and pyrazinamide ultimately concluded that 
overall, drug discontinuation due to hepatotoxicity occurred 
in 2.0%–17.6% of HIV-negative patients and 0%–9.5% in 
patients with HIV co-infection.51 Accordingly, this regimen 
is no longer recommended in international guidelines.
Isoniazid and rifampicin
Three or four month courses of isoniazid and rifampicin were 
at least equivalent to 9 months of isoniazid alone in one ran-
domized controlled trial in children ,15 years old.63 In this 
study, 926 children diagnosed with LTBI were randomized 
to either a short course or standard isoniazid regimen, and 
followed for a minimum of 3 years post-treatment. Greater 
compliance (78%–89% vs 65.5%) was seen in children 
prescribed short course regimens.
Subjects who received short course therapy were also 
found to have less radiologic change suggesting active dis-
ease during follow up (11% vs 24%); however, no child from 
either group experienced a clinically and microbiologically 
diagnosed episode of active tuberculosis. 6% of children 
who received isoniazid therapy developed transient increases 
in liver enzymes, which was seen in 1.2% of short-course 
recipients. No patient from either group experienced severe 
hepatotoxicity or required treatment cessation for adverse 
effects.
Isoniazid and rifapentine
The combination of isoniazid and rifapentine has been of 
recent interest in the treatment of LTBI. Rifapentine is a 
long-acting rifamycin that has been used successfully as 
a weekly dose in the continuation phase of treatment for 
active TB, and has been shown in animal models to be 
effective against latent TB.64–66 Reviews of its use in the 
treatment of active tuberculosis suggest that it is generally 
well-tolerated in this setting, and associated with low rates 
of serious adverse effects.67
Weekly isoniazid (900 mg) and rifapentine (900 mg) 
for 12 weeks has been compared to daily rifampicin and 
pyrazinamide in household contacts of pulmonary TB.68 
Contacts treated with weekly dosing were less likely to 
develop hepatotoxicity (1% vs 10%). However, this regi-
men may have been slightly less effective, with active TB 
infections occurring at a rate of 0.5 per 100 patient-years in 
the weekly dosing regimen versus 0.2 in the daily rifampicin 
and pyrazinamide group. This difference was not statisti-
cally significant, and both groups experienced substantially 
less active disease than expected from local background 
rates of 4% annually.69 The combination of rifapentine and 
moxifloxacin has not been evaluated in humans, however it 
demonstrated equal efficacy with rifapentine and isoniazid 
in a mouse model of LTBI.70
Rifapentine appears to be a well-tolerated medication, 
with potential for shortening courses of LTBI therapy. 
Further investigation is required into the comparative effec-
tiveness of intermittent rifapentine-containing regimens, 
and the potential for development of multidrug resistance 
during therapy.
Treatment of suspected multidrug-
resistant latent tuberculosis
As reviewed above, the considerable bulk of therapies inves-
tigated for the treatment of latent TB infection are intended 
for infections with isolates sensitive to first-line tuberculosis 
medications. However, with an increasing global burden of 
multidrug-resistant tuberculosis (MDR TB), the presumption 
of infection caused by drug-sensitive TB isolates may not 
be justified in some clinical settings. Most commonly, this 
relates to people known to have been significantly exposed 
to a source of sputum smear-positive MDR TB. However, 
where patients are epidemiologically likely to have acquired 
LTBI in settings with very high prevalence of MDR TB it 
may also be questioned whether treatment of latent infec-
tion should include the possibility of multidrug-resistance 
de novo. It has been suggested that latent MDR TB may 
be less likely to reactivate than infection caused by drug-
susceptible organisms, a finding supported by notification 
data in at least one national surveillance program.71,72 It is 
presently difficult to quantify the likelihood of reactivation 
MDR TB, however, and the consequences of developing 
active infection are significant.
Evidence for treatment of LTBI in such settings is 
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nonrandomized studies considering the effectiveness of 
LTBI treatment in contacts of known MDR TB index cases.73 
One prospective study individualized medications included 
in the treatment regimen based on the sensitivity testing 
results from the household contact. Medications prescribed 
included high-dose isoniazid (15–20 mg/kg), ethambutol, 
ofloxacin and ethionamide. From 105 children with house-
hold contact, 41 received individualized therapy. During a 
30-month follow-up period, 2 of 41 (5%) developed active 
TB infection, compared with 13 of the 64 (20%) who had 
not received chemoprophylaxis. A further study retrospec-
tively evaluated the impact of high-dose isoniazid preventive 
therapy on close contacts of index patients with MDR TB.69 
A 6-month course of 400 mg/day of isoniazid was initiated 
for 45 contacts of index patients with tuberculosis, with two 
contacts subsequently developing active TB. Both of the 
breakthrough contacts had MDR-TB, as did their index cases. 
More recently, individualized regimens for treating LTBI 
have also been used by the US Centers for Disease Control 
in the setting of MDR-TB outbreaks in Micronesia, although 
little data has yet been reported regarding effectiveness.74 
By contrast, on the basis of limited available evidence, the 
WHO does not recommend the use of second-line agents 
for treating LTBI.26
Even in settings where rates of active MDR TB are extre-
mely high, such as countries of the former Soviet Union, it is 
unlikely that the routine use of second-line antituberculosis 
medications for LTBI will be justifiable given the risks of 
subsequent re-infection and contributing to further drug resis-
tance. However, individualized treatment regimens may be 
considered in patients based on sensitivity testing in contact 
isolates and personal risk/benefit considerations.
Cost-effectiveness
The relative cost-effectiveness of various regimens for treat-
ment of LTBI has been evaluated in several recent studies. 
Ziakas and Mylonakis compared nine months of daily isoni-
azid with 4 months of daily rifampicin using meta-analysis 
of 3586 published patients in four head-to-head trials.75 They 
conclude that rifampicin therapy is associated with signifi-
cantly decreased discontinuation rates (RR 0.53; 95% CI: 
0.44–0.63), hepatotoxicity (RR 0.12; 95% CI: 0.05–0.3) 
and decreased cost (USD 972.20 vs 1062.50) than 9 months 
of isoniazid. However, the difference in cost in this analysis 
was heavily influenced by the use of laboratory testing, which 
assumed monthly testing of liver function and complete blood 
counts in all patients. Such testing is arguably unnecessary 
in low risk patients with normal baseline investigation, and 
may result in unwarranted discontinuation of therapy due 
to mild abnormalities.76 Due to higher cost of rifampicin 
medication, cost-effectiveness comparison would favor iso-
niazid if monthly testing were not performed. Nonetheless, 
frequent laboratory testing is performed in many countries, 
and this analysis suggests the superior cost-effectiveness 
of rifampicin under such conditions. A second analysis of 
cost-effectiveness used a mathematical model that included 
broader societal and health care costs in the analysis, and 
also suggested that rifampicin was more cost-effective than 
isoniazid based regimens.77 Both studies highlight the benefits 
associated with shorter courses of effective LTBI therapy, and 
suggest that improved completion rates are likely to offset 
the higher medication cost of rifampicin.
Novel and emerging therapies
Currently, a number of novel pharmacologic agents with 
activity against M. tuberculosis are in various phases of 
development.67 Several of these medications have begun 
preliminary assessment in animal models of LTBI, including 
moxifloxacin and PA-824(70). Although most novel agents 
have not been directly assessed in the treatment of LTBI, 
a larger spectrum of available agents will provide greater 
options for tuberculous therapy and may yield new possibili-
ties for LTBI treatment.
Ultimately, it would be advantageous if LTBI could be 
treated with a different class of drug from those used for 
active tuberculosis, reducing concerns regarding the uncer-
tainty of drug resistance patterns in patients with LTBI, as 
well as limiting the possibility of resistant active TB follow-
ing failed therapy.
Non-pharmacological therapies
Finally, the future potential for non-drug treatments for 
eradication of LTBI, particularly vaccines and other immu-
notherapies, remains to be fully explored. Vaccines against 
tuberculosis have been most often conceived as tools for 
preventing establishment of latent disease or the subsequent 
emergence of active infection, however more recently there 
has been interest in the development of vaccines that augment 
eradication of LTBI.78,79 The existing BCG vaccine has a mod-
erate capacity for reducing active infection rates, but no role 
in post-exposure management of LTBI.80–82 However, several 
novel DNA and subunit vaccines have demonstrated some 
promise in animal models. One study in a murine LTBI model 
found that therapeutic DNA vaccination had no effect on 
reactivation, but when used in conjunction with   moxifloxacin 
treatment augmented its bactericidal effects.70 An alternative Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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therapeutic vaccine, RUTI, involving liposomally delivered 
fragmented M. tuberculosis cells, has also been shown to 
enhance the effect of short-course chemotherapy in animal 
models, with ongoing clinical trials continuing.83,84 Effective 
vaccines against the latent phase of tuberculosis infection 
would be a welcome adjunct to LTBI management but remain 
distant from clinical use at present.
Non-vaccine immunotherapy has perhaps been con-
sidered more frequently in non-tuberculous mycobacte-
rial infections, however may be of benefit in TB also, 
  particularly in the setting of extensively drug-resistant 
infection.85 Investigations into intravenous immunoglobu-
lin (IVIg) and 16α-bromoepiandrosterone (HE2000) have 
shown antituberculosis effect, while adjunctive therapy 
with thalidomide analogue CC-3052 enhances mycobacte-
rial clearance.85–88 One small study suggested that adjunc-
tive IL-2 may reduce the duration of smear-positivity 
during treatment of pulmonary TB, however a subsequent 
RCT did not confirm this finding.88,89 GM-CSF increases 
phagocytosis of non-tuberculous mycobacteria, and has 
also been shown to reduce mycobacterial persistence in a 
murine lung model.90,91 Overall, trials of immunotherapy 
have so far largely concentrated on animal models of active 
infection however they may have a future role in shorten-
ing LTBI treatment regimens when used as adjunctive 
therapy.
Summary
Current LTBI therapy is limited by long courses of   treatment 
with concomitant poor adherence, side effects, and   uncertain 
effectiveness in the individual patient. Moreover, the effec-
tiveness of strategies for treating latent tuberculosis may 
be potentially threatened in many areas by rising rates 
of drug resistance. To optimize LTBI management in the 
future, effective short course therapies must be further 
investigated and instituted, particularly with randomized 
studies comparing 9 months of isoniazid therapy against 
alternative regimens.
Further research and clinical experience in the   management 
of MDR-LTBI is imperative, and will become   increasingly 
important in the future. As rates of active tuberculosis   infection 
fall worldwide, appropriate diagnosis and management of 
LTBI become increasingly important, particularly in countries 
that have already achieved low prevalence of active disease.
Finally, refinement in epidemiologic approaches to under-
standing LTBI prevalence and reactivation will be important 
for translating individual treatment programs into the plan-
ning and assessment of effective public health strategies.
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